BiomX reported a FY 2025 net loss of USD 36.20 million, compared with USD 17.73 million in FY 2024. The clinical-stage phage-therapy developer said it had no revenue from product sales, and recorded an operating loss of USD 41.47 million in FY 2025. R&D expenses, net were USD 21.29 million in FY 2025 (-14%), while general and administrative expenses were USD 9.63 million (-19%). The company booked an IPR&D impairment charge of USD 11.84 million and other long-lived asset impairment of USD 1.65 million in FY 2025, alongside a gain from early lease termination of USD 2.95 million. Cash, cash equivalents and restricted cash totaled USD 5.00 million as of Dec. 31, 2025, and the company said its funds are expected to support operations only through the end of Q2 2026, raising substantial doubt about its ability to continue as a going concern. For corporate updates, BiomX said it discontinued development of BX004 in December 2025 following adverse events and feedback from the data monitoring committee, and implemented cost-cutting measures including a significant workforce reduction. The company also said its Israeli subsidiary, BiomX Ltd., commenced insolvency proceedings in December 2025, materially impacting operations. BiomX highlighted a Dec. 26, 2025 private placement for gross proceeds of USD 3.00 million, issuing 3,300 shares of newly created Series Y convertible preferred stock (USD 3.30 million aggregate stated value) and warrants to purchase up to 3,300,000 common shares; the company said completion of related stockholder approval is key to its financing options and future strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BiomX Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-018231), on February 19, 2026, and is solely responsible for the information contained therein.